Live
- About 77% voter turnout in bypolls in 3 Assembly segments
- How NGOs are playing a crucial role in supporting female leadership
- Gold rates in Hyderabad today slashes, check the rates on 14 November, 2024
- Karnataka to Host global ‘Startup-VC Connect’ at Bengaluru Tech Summit 2024
- Gold rates in Visakhapatnam today slashes, check the rates on 14 November, 2024
- Doctors Demand Action After Violent Attack on Healthcare Workers in Tamil Nadu
- Gut health holds key to managing diabetes
- Bengaluru: Entrance fee of Bala Bhavan to be hiked
- Indian Institute of Creative Technology to open centre in city
- Darshan interim bail: HM appeals to SC to vacate stay
Dr Reddy's net zooms 30% to Rs 992 cr in Q2
Dr Reddy’s net zooms 30% to Rs 992 cr in Q2
Drug maker has posted a net profit of `762.3 crore for the corresponding period in FY21
Hyderabad: Drug major Dr Reddy's Laboratories on Friday reported a 30 per cent jump in its consolidated net profit to Rs 992 crore for the quarter ended September 30, 2021, on account of other income and robust sales in all markets.
The company had posted a net profit of Rs 762.3 crore for the corresponding period of the previous financial year, Dr Reddy's Laboratories said in a press release.Its consolidated revenue during July-September 2021 stood at Rs 5,763.2 crore. It was Rs 4,896.7 crore in the year-ago period, it added.
"I am pleased with the improvement in the financial performance across our businesses.
While we continue to strengthen our core businesses of genericsand APls (active pharmaceutical ingredients), we are also making investments in our long-term growth drivers and deeper innovation capabilities," Dr Reddy'sLaboratories co-Chairman and Managing Director G V Prasad said.Under the Covid-19 products basket, the drug maker launched Sputnik V vaccine, remdesivir, avigan and 2-deoxy-D-glucose (2-DG) till now.
